No Data
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Can you slim down just by taking Simiglutide? Doctors say it is ineffective for about 15% of people, and medication needs to be accompanied by dietary adjustments.
On November 23, Gelonghui reported that the weight loss drug "semaglutide" (Novo Nordisk) was officially announced for commercial launch in the country on November 17. As the weight loss version of "semaglutide" enters medical institutions, the consultation volume for relevant weight loss and endocrine clinics is gradually increasing. Recently, a reporter interviewed Han Xiaodong, a weight loss and metabolic surgery doctor at Shanghai Sixth People's Hospital, who stated that the use of Novo Nordisk has strict indications, and obese patients with clinical weight loss needs should go to regular medical institutions for evaluation and diagnosis to initiate scientific weight loss treatment. "The use of weight loss drugs needs to be standardized.
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $156
Smart Money Is Betting Big In NVO Options
Unusual Options Activity: LRCX, COIN and Others Attract Market Bets, LRCX V/OI Ratio Reaches 119.0
EST Nov 22nd Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options